Scholarlink

Background <p>Inborn errors of metabolism (IEMs) are among the most clinically actionable groups of rare genetic diseases, yet therapeutic knowledge remains distributed across multiple databases, complicating consistent identification of treatable IEMs.</p> Methods <p>In this study, we performed a cross-database analysis to characterize the current therapeutic landscape of IEM genes using GeneReviews as a clinical reference. Gene symbols from GeneReviews, Metabolic Treatabolome, Treatable ID, and the Drug Database for Inborn Errors of Metabolism (DDIEM) were harmonized to HGNC nomenclature and mapped to the International Classification of Inherited Metabolic Disorders (ICIMD). IEM genes were categorized as associated with targeted or supportive treatment based on a GeneReviews-derived benchmark.</p> Results <p>Among 656 ICIMD-defined IEM genes in GeneReviews, 155 (23.6%) were associated with targeted therapies and 501 (76.4%) with supportive treatment. Cross-database comparison demonstrated limited concordance, with only 36 genes associated with targeted therapy shared across Metabolic Treatabolome, Treatable ID, and DDIEM, reflecting heterogeneous representation of treatable IEMs across databases. Targeted therapies were more common in intermediary metabolic pathways, including fatty acid, tetrapyrrole, and vitamin/cofactor metabolism, whereas mitochondrial and complex cellular disorders were predominantly associated with supportive management. Moreover, 53% of the ICIMD-defined IEM genes remain unrepresented in structured databases.</p> Conclusions <p>Our study defines a set of IEM genes for which targeted therapies are available and demonstrates that treatment information is largely fragmented across databases. This set of IEM genes may facilitate the interpretation of genomic findings and aid the prioritization of IEMs for genomic screening and clinical decision-making.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Mapping the landscape of treatable inborn errors of metabolism: a systematic gene-level evaluation based on the ICIMD classification

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月3日

查看全文
  • Tabeer Fatima,
  • Jalal Khan,
  • Fatma Al-Jasmi,
  • Hiba Alblooshi

摘要

Background

Inborn errors of metabolism (IEMs) are among the most clinically actionable groups of rare genetic diseases, yet therapeutic knowledge remains distributed across multiple databases, complicating consistent identification of treatable IEMs.

Methods

In this study, we performed a cross-database analysis to characterize the current therapeutic landscape of IEM genes using GeneReviews as a clinical reference. Gene symbols from GeneReviews, Metabolic Treatabolome, Treatable ID, and the Drug Database for Inborn Errors of Metabolism (DDIEM) were harmonized to HGNC nomenclature and mapped to the International Classification of Inherited Metabolic Disorders (ICIMD). IEM genes were categorized as associated with targeted or supportive treatment based on a GeneReviews-derived benchmark.

Results

Among 656 ICIMD-defined IEM genes in GeneReviews, 155 (23.6%) were associated with targeted therapies and 501 (76.4%) with supportive treatment. Cross-database comparison demonstrated limited concordance, with only 36 genes associated with targeted therapy shared across Metabolic Treatabolome, Treatable ID, and DDIEM, reflecting heterogeneous representation of treatable IEMs across databases. Targeted therapies were more common in intermediary metabolic pathways, including fatty acid, tetrapyrrole, and vitamin/cofactor metabolism, whereas mitochondrial and complex cellular disorders were predominantly associated with supportive management. Moreover, 53% of the ICIMD-defined IEM genes remain unrepresented in structured databases.

Conclusions

Our study defines a set of IEM genes for which targeted therapies are available and demonstrates that treatment information is largely fragmented across databases. This set of IEM genes may facilitate the interpretation of genomic findings and aid the prioritization of IEMs for genomic screening and clinical decision-making.